Vicore Pharma Holding AB (VCRE) Stock Analysis

AI analysis of Vicore Pharma Holding AB (VCRE)

sell

Vicore Pharma Holding AB (VCRE) is not a good buy right now due to its significant negative performance and weak technical indicators. The stock has a current price of 11.31, with a year-to-date change of -30.40%, indicating a substantial decline. Additionally, the RSI is at 40.642, suggesting the stock is nearing oversold territory but not yet at a strong buy signal. The forward P/E ratio is 0, indicating no earnings growth expectations, which raises concerns about its future profitability. The main risk is its negative price-to-earnings ratio of -0.66, indicating the company is currently unprofitable. Overall, the combination of declining performance and lack of positive catalysts makes this stock a sell.

Valuation Metrics

The current forward P/E ratio for Vicore Pharma Holding AB (VCRE) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E

Current P/E

0.00

Forward EV/EBITDA

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Forward P/S

Fair

5Y Average P/S

23.09

Current P/S

5.21

Overvalued

54.98

Undervalued

-8.80

VCRE FAQ — answered by Alphio AI

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB. It operates in the Healthcare sector.

Vicore Pharma Holding AB (VCRE) is not a good buy right now due to its significant negative performance and weak technical indicators. The stock has a current price of 11.31, with a year-to-date change of -30.40%, indicating a substantial decline. Additionally, the RSI is at 40.642, suggesting the stock is nearing oversold territory but not yet at a strong buy signal. The forward P/E ratio is 0, indicating no earnings growth expectations, which raises concerns about its future profitability. The main risk is its negative price-to-earnings ratio of -0.66, indicating the company is currently unprofitable. Overall, the combination of declining performance and lack of positive catalysts makes this stock a sell.